Sign in
TerminatedPhase 2/3

Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

Key facts

Who runs it
LeonaBio
Where
Rochester, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 2/3
People taking part
423 people enrolled
Started
30 Jun 2021
Ended
23 Oct 2024
Type of study
Interventional
Treatments tested
  • ATH-1017
Record updated
1 April 2025
Why it stopped
ATH-1017-AD-0203 was terminated after the Ph2/3 parent trial (LIFT-AD; NCT04488419) did not meet its primary endpoint, the GST score.

Who can take part

Age
55 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Subject has completed the Week 26 visit of either of the two blinded parent studies (ATH-1017-AD-0201 or ATH-1017-AD-0202)
  • Reliable and capable support person/caregiver who is willing to accept responsibility for supervising the daily treatment or, if required, administering study drug
  • Subject capable of giving signed informed consent, or by a legally acceptable representative
  • Subjects must be in generally good health
  • Male subjects and their partners must agree to continue to use a double-barrier method of contraception during the study, including the follow-up period, unless the partner is not of childbearing potential

Who cannot take part

  • New diagnosis of severe major depressive disorder even without psychotic features
  • Newly-diagnosed malignant tumor, except for the following conditions that are stable in the judgement of the investigator:; Adequately treated squamous and basal cell carcinoma, or squamous and basal cell carcinoma in situ; Prostate carcinoma in situ
  • Subject has experienced a serious adverse event during the parent study, which could present an increased safety risk during the open label extension
  • Any subject with formalized delusions or hallucinations
  • Significant suicide risk

Where in United States

  • University of Rochester-AD-CARE ProgramRochester, United States

About the trial

What the trial wants to find out

The objective of this study is to determine the safety and tolerability of fosgonimeton (ATH-1017) in subjects with mild to moderate Alzheimer's disease who completed the 26-week randomized treatment in Study ATH-1017-AD-0201 or Study ATH-1017-AD-0202.

The group in the trial

  • TreatmentTreatment being tested

    Daily subcutaneous (SC) injection of ATH-1017 - 40mg Dosage

    Treatment: ATH-1017

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Open-Label Extension of Studies ATH-1017-AD-0201 and ATH-1017-AD-0202 in Subjects With Mild to Moderate Alzheimer's Disease
Publications
Record updated
1 April 2025